CorMedix Inc. (CRMD), a biopharmaceutical company, Tuesday reported preliminary revenue of $39 million for the first quarter. In the previous-year quarter, the company did not receive any revenue.
CorMedix sees adjusted EBITDA, or adjusted earnings before interest, taxes, depreciation, and amortization to be more than $22.5 million for the quarter.
For the first half, the company has raised its net sales to existing purchasing customers outlook to a range of $62 million to $70 million, from $50 million - $60 million guided earlier.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.